Treatment
Nerandomilast clinical trials
We’re tracking 6 recruiting studies that include Nerandomilast, each written for real people, not researchers, below.
Recruiting studies
- NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Birmingham, AlabamaAges 18 years+ - NCT06806592RecruitingPhase 3
Testing nerandomilast for lung scarring from rheumatic disease
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
Birmingham, AlabamaAges 18 years+ - NCT06238622RecruitingPhase 3
Long-term nerandomilast for pulmonary fibrosis follow-up
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
Birmingham, AlabamaAges 18 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Los Angeles, CaliforniaAges 40 years+ - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Los Angeles, CaliforniaAges 2–17 - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+
What Nerandomilast is being studied for
Conditions with recruiting Nerandomilast studies.
Common questions
- Are there clinical trials studying Nerandomilast?
- Yes. Clin2 currently lists 6 recruiting studies that include Nerandomilast, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Nerandomilast trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Nerandomilast an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Nerandomilast or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.